Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/echoiq-limited">ECHOiQ</a> is a pre-commercialization medical technology company with a potentially disruptive AI-powered platform, EchoSolv™, targeting the significant market of cardiovascular disease diagnostics.</li>
 <li>The company has achieved key regulatory milestones, including FDA clearance for its Aortic Stenosis product (EchoSolv-AS), and is focused on a US-centric commercialization strategy through strategic partnerships.</li>
 <li>Significant financial risks exist, as the company is not yet profitable, has negligible revenue, and maintains a high cash burn rate, making its valuation entirely dependent on future successful commercialization and market adoption.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
ECHOiQ is a pre-commercialization medical technology company with a potentially disruptive AI-powered platform, EchoSolv™, targeting the significant market of cardiovascular disease diagnostics.
  The company has achieved key regulatory milestones, including FDA clearance for its Aortic Stenosis product (EchoSolv-AS), and is focused on a US-centric commercialization strategy through strategic partnerships.
  Significant financial risks exist, as the company is not yet profitable, has negligible revenue, and maintains a high cash burn rate, making its valuation entirely dependent on future successful commercialization and market adoption.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 28th September, published on the 2nd October.
</li>
<li>The largest industry net increase in the past week was A$0.4bn into "Banks"; the largest industry net decrease was A$0.1bn out of "Interactive Media". Net shorts increased A$0.5bn week-on-week. 
</li>
<li>Companies mentioned in this regular weekly report include: <a href="https://www.smartkarma.com/entities/bhp-group-ltd" target="_blank" data-smartkarma-citation="entities:147:1" rel="noopener">BHP Group (BHP AU)</a>, <a href="https://www.smartkarma.com/entities/steadfast-group-ltd" target="_blank" data-smartkarma-citation="entities:8181:1" rel="noopener">Steadfast (SDF AU)</a>, <a href="https://www.smartkarma.com/entities/artrya-ltd" target="_blank" data-smartkarma-citation="entities:41151:1" rel="noopener">Artrya (AYA AU)</a>, <a href="https://www.smartkarma.com/entities/echoiq-limited" target="_blank" data-smartkarma-citation="entities:8230:1" rel="noopener">ECHOiQ (EIQ AU)</a>, <a href="https://www.smartkarma.com/entities/catalyst-metals-ltd" target="_blank" data-smartkarma-citation="entities:4293:1" rel="noopener">Catalyst Metals (CYL AU)</a>, and <a href="https://www.smartkarma.com/entities/core-lithium-ltd" target="_blank" data-smartkarma-citation="entities:14712:1" rel="noopener">Core Lithium (CXO AU)</a>.</li>
</ul>


Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 28th September, published on the 2nd October.

The largest industry net increase in the past week was A$0.4bn into "Banks"; the largest industry net decrease was A$0.1bn out of "Interactive Media". Net shorts increased A$0.5bn week-on-week. 

Companies mentioned in this regular weekly report include: BHP Group (BHP AU), Steadfast (SDF AU), Artrya (AYA AU), ECHOiQ (EIQ AU), Catalyst Metals (CYL AU), and Core Lithium (CXO AU).


Aussie Shorts [28 Sep 2026]: BHP Group, Steadfast, Artrya, ECHOiQ, Catalyst Metals, Core Lithium

<ul>
<li>It's a weak stub. And given <a href="https://www.smartkarma.com/entities/inpex-corp" target="_blank" data-smartkarma-citation="entities:20665:1" rel="noopener">Inpex Corp (1605 JP)</a>'s direct upstream ops amid high crude oil prices, I'd be disinclined to short the company here against <a href="https://www.smartkarma.com/entities/japan-petroleum-exploration" target="_blank" data-smartkarma-citation="entities:12219:1" rel="noopener">JAPEX (1662 JP)</a>.</li>
<li>Keswick chips away at <a href="https://www.smartkarma.com/entities/jardine-matheson-holdings-limited" target="_blank" data-smartkarma-citation="entities:19718:1" rel="noopener">Jardine Matheson (JM SP)</a>'s minorities via scrip dividends and buybacks; as JMH completes the  US$2.4bn i-Med acquisition. </li>
<li>
<a href="https://www.smartkarma.com/entities/jardine-matheson-southeast-asia-ltd" target="_blank" data-smartkarma-citation="entities:347:1" rel="noopener">Jardine Matheson Southeast Asia (JCNC SP)</a> (formerly known as Jardine Cycle &amp; Carriage), popped ~10% ahead of the <a href="https://www.smartkarma.com/entities/toyota-motor-corp" target="_blank" data-smartkarma-citation="entities:73:1" rel="noopener">Toyota Motor (7203 JP)</a> in-specie-distribution and special dividend.</li>
</ul>


It's a weak stub. And given Inpex Corp (1605 JP)'s direct upstream ops amid high crude oil prices, I'd be disinclined to short the company here against JAPEX (1662 JP).
Keswick chips away at Jardine Matheson (JM SP)'s minorities via scrip dividends and buybacks; as JMH completes the  US$2.4bn i-Med acquisition. 

Jardine Matheson Southeast Asia (JCNC SP) (formerly known as Jardine Cycle &amp; Carriage), popped ~10% ahead of the Toyota Motor (7203 JP) in-specie-distribution and special dividend.


Last Week In Event SPACE: Inpex, Jardine Matheson, Jardine Matheson Southeast Asia, Genting

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Sep 25th (reported today). The aggregated short interest was USD49.0bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Steadfast, Wesfarmers, Macquarie, Ampol, BHP.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Sep 25th (reported today). The aggregated short interest was USD49.0bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Steadfast, Wesfarmers, Macquarie, Ampol, BHP.


ASX Short Interest Weekly (Sep 25th): Steadfast, Wesfarmers, Macquarie, Ampol, BHP

Institutional-Quality Issuer Sponsored Research, Venn Brown

Venn Brown

Institutional-Quality Issuer Sponsored Research

Venn Brown is a specialist Australian micro and small-cap research house. Our coverage includes health care, information technology, industrials, financials, biotech and consumer/retail.

<ul><li>Artrya fell -21% last week and at one point, was down another -8% today.</li><li>At today’s close, the shares are down -50% from their all-time high of $6.49 set just three months ago on the 6th July.</li><li>The pullback is partly a result of disappointing 4Q26 results (see ‘Valuation downgrade but market overreaction is a buying opportunity’) compounded by 1) last Tuesday’s rejection by the FDA of EchoIQ’s EchoSolv HF submission; and 2) the ongoing delay in Salix Coronary Flow FDA submission.</li></ul>

Artrya fell -21% last week and at one point, was down another -8% today.At today’s close, the shares are down -50% from their all-time high of $6.49 set just three months ago on the 6th July.The pullback is partly a result of disappointing 4Q26 results (see ‘Valuation downgrade but market overreaction is a buying opportunity’) compounded by 1) last Tuesday’s rejection by the FDA of EchoIQ’s EchoSolv HF submission; and 2) the ongoing delay in Salix Coronary Flow FDA submission.

Artrya (ASX:AYA): Share price dragged down by EchoIQ FDA denial; AYA joins S&P/ASX 300; Scenario test the robustness of our forecasts maintain $6.07 per share valuation

Australia

ECHOiQ Limited operates as a software company. The Company offers technology platform that captures and applies interpretive models to specific conditions across healthcare sectors. ECHOiQ serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ECHOiQ (EIQ AU)

Primer: ECHOiQ (EIQ AU) - Aug 2026

ECHOiQ is a pre-commercialization medical technology company with a potentially disruptive AI-powered platform, EchoSolv™, targeting the...

αSK Primers

Aussie Shorts [28 Sep 2026]: BHP Group, Steadfast, Artrya, ECHOiQ, Catalyst Metals, Core Lithium

The largest industry net increase in the past week was A$0.4bn into "Banks"; the largest industry net decrease was A$0.1bn out of "Interactive...

David Blennerhassett

Last Week In Event SPACE: Inpex, Jardine Matheson, Jardine Matheson Southeast Asia, Genting

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

ASX Short Interest Weekly (Sep 25th): Steadfast, Wesfarmers, Macquarie, Ampol, BHP

We analyzed ASX short interest report for the past week and highlight short interest changes in Steadfast, Wesfarmers, Macquarie, Ampol, BHP.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: ECHOiQ (EIQ AU) - Aug 2026

ECHOiQ is a pre-commercialization medical technology company with a potentially disruptive AI-powered platform, EchoSolv™, targeting the...

αSK Primers

Aussie Shorts [28 Sep 2026]: BHP Group, Steadfast, Artrya, ECHOiQ, Catalyst Metals, Core Lithium

The largest industry net increase in the past week was A$0.4bn into "Banks"; the largest industry net decrease was A$0.1bn out of "Interactive...

David Blennerhassett

Last Week In Event SPACE: Inpex, Jardine Matheson, Jardine Matheson Southeast Asia, Genting

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

ASX Short Interest Weekly (Sep 25th): Steadfast, Wesfarmers, Macquarie, Ampol, BHP

We analyzed ASX short interest report for the past week and highlight short interest changes in Steadfast, Wesfarmers, Macquarie, Ampol, BHP.

Ke Yan, CFA, FRM

Artrya (ASX:AYA): Share price dragged down by EchoIQ FDA denial; AYA joins S&P/ASX 300; Scenario test the robustness of our forecasts maintain $6.07 per share valuation

Artrya fell -21% last week and at one point, was down another -8% today. At today’s close, the shares are down -50% from their all-time high of...

Venn Brown